On World Contraception Day, Organon, a pharmaceutical company focused on women’s health, ignited discussions on women’s ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

In recognition of World Contraception Day (WCD) on September 26, Organon Canada, a subsidiary of Organon (NYSE: OGN), a ...

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential ...

Organon & Co (OGN) stock saw a decline, ending the day at $19.66 which represents a decrease of $-0.06 or -0.30% from the prior close of $19.72. The stock opened at $19.8 and touched a low of $19.51 ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

ON World Contraception Day, Organon, a pharmaceutical company focused on women's health, ignited discussions on women's ...